Reducing Mortality in Adults With Advanced HIV Disease (REVIVE) (REVIVE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05580666 |
Recruitment Status :
Recruiting
First Posted : October 14, 2022
Last Update Posted : March 26, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Disease Progression | Drug: Azithromycin Oral Tablet Drug: Placebo oral tablet | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 8000 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Double blinded placebo-controlled randomized trial |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: | Double blinded placebo-controlled |
Primary Purpose: | Treatment |
Official Title: | Reducing Mortality in Adults With Advanced HIV Disease, a Double Blinded Randomized Trial |
Actual Study Start Date : | May 8, 2023 |
Estimated Primary Completion Date : | May 31, 2028 |
Estimated Study Completion Date : | August 1, 2028 |
Arm | Intervention/treatment |
---|---|
Experimental: Oral Azithromycin 250 mg once daily
Active Azithromycin tablet
|
Drug: Azithromycin Oral Tablet
Antimicrobial therapy |
Placebo Comparator: Oral matching placebo, once daily
Matching placebo tablet
|
Drug: Placebo oral tablet
Inert ingredients |
- All-cause mortality [ Time Frame: 24 weeks after randomization ]All-cause mortality over the first 24 weeks after randomization
- All-cause mortality [ Time Frame: 12 weeks after randomization ]All-cause mortality over the first 12 weeks after randomization
- Hospitalization [ Time Frame: 24 weeks after randomization ]Hospitalization over the first 24 weeks after randomization
- Composite of hospitalization or all-cause mortality [ Time Frame: 24 weeks after randomization ]Composite of hospitalization or all-cause mortality over the first 24 weeks after randomization
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 18 years
- Documented HIV infection
-
CD4 count criteria:
i. CD4 count ≤ 100 cells/mm3 within past 4 weeks; or
ii. Documented CD4 nadir ≤ 100 cells/mm3 and complete interruption of ART for ≥ 6 months; or
iii. Documented CD4 count ≤ 100 cells/mm3 if ART-naive
- Ability to initiate or re-initiate ART, or switch to an effective ART regimen if failing current therapy, within 4 weeks of enrolment
Exclusion Criteria:
-
Contraindications to azithromycin:
i. Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic; or
ii. Personal or family history of QT-prolongation
- Severe illness requiring immediate or continued hospitalization (this will be in the judgment of site investigators)
- Off-label azithromycin prophylaxis or requirement for prolonged (> 7 days) azithromycin (or macrolide) therapy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05580666
Contact: REVIVE Study Coordinator | 905-297-3479 | revive@phri.ca |
Principal Investigator: | John Eikelboom, MBBS, MSc, FRCPC | Population Health Research Institute | |
Principal Investigator: | Sean Wasserman, MBChB, PhD | University of Cape Town |
Responsible Party: | Population Health Research Institute |
ClinicalTrials.gov Identifier: | NCT05580666 |
Other Study ID Numbers: |
PHRI.REVIVE |
First Posted: | October 14, 2022 Key Record Dates |
Last Update Posted: | March 26, 2024 |
Last Verified: | March 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Human immunodeficiency virus Antiretroviral therapy Azithromycin Mortality |
Acquired Immunodeficiency Syndrome HIV Infections Disease Progression Disease Attributes Pathologic Processes Blood-Borne Infections Communicable Diseases Infections Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Lentivirus Infections |
Retroviridae Infections RNA Virus Infections Virus Diseases Slow Virus Diseases Genital Diseases Urogenital Diseases Immunologic Deficiency Syndromes Immune System Diseases Azithromycin Anti-Bacterial Agents Anti-Infective Agents |